Aortic Stenosis, Heart Failure, and Aortic Valve Replacement
JAMA Cardiology
OCTOBER 15, 2024
This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement.
DAPA-TAVI: Dapagliflozin Safe and Effective in Older Adults With HF Undergoing TAVI
American College of Cardiology
MARCH 29, 2025
25 in Chicago and simultaneously published in the NEJM.
Severe Aortic Stenosis, Titration and Acute Heart Failure, Pacemakers After TAVR
American College of Cardiology
JUNE 18, 2024
In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure.
Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
DAIC
MARCH 28, 2024
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Aortic stenosis.
TAVR 
111
111 
Systematic review and meta-analysis of early aortic valve replacement versus conservative therapy in patients with asymptomatic aortic valve stenosis with preserved left ventricle systolic function
Open Heart
JANUARY 8, 2024
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
Aortic valve 98
98 
Aortic valve replacement in a bicuspid aortic valve patient followed by reoperation for ascending aorta rupture: a case report
Frontiers in Cardiovascular Medicine
DECEMBER 11, 2024
Bicuspid aortic valve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration. In the sixth postoperative year, she was readmitted due to ascending aorta rupture, resulting in blood entering the right atrium and causing acute right heart failure.
Aortic valve 52
52 
Eagle’s Eye View: Sacubitril/Valsartan in Decompensated Heart Failure; Discordant Aortic Stenosis and Transcatheter Treatment of Tricuspid Valve Regurgitation
American College of Cardiology
MARCH 27, 2024
In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.
Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure
CardiacWire
JULY 28, 2024
Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
Transcatheter aortic valve replacement in patients with systolic heart failure, aortic stenosis shows limited benefits
Medical Xpress - Cardiology
OCTOBER 29, 2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Aortic valve 45
45 
Aortic Stenosis, Heart Failure, and Aortic Valve Replacement: Key Points
American College of Cardiology
DECEMBER 17, 2024
The following are key points to remember from a review on aortic stenosis (AS), heart failure (HF), and aortic valve replacement (AVR).
Aortic valve 40
40 
Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real‐World Evaluation of Clinical Characteristics and Outcomes
Journal of the American Heart Association
JANUARY 16, 2025
Journal of the American Heart Association, Ahead of Print. BackgroundThe coexistence of transthyretin cardiac amyloidosis (ATTRCA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. P=0.003) but not heart failure hospitalization (HR, 1.1 [95% 95% CI, 1.11.4];P<0.0001)
Aortic 73
73 
Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC
European Journal of Heart Failure
FEBRUARY 26, 2025
Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.
AHA Raises Awareness on HVD
DAIC
MARCH 4, 2025
The Most Common Form of HVD One of the most prevalent and serious forms of heart valve disease is aortic stenosis (AS), a condition characterized by the narrowing of the aortic valve opening, which affects approximately 5% of adults over 65a number expected to more than double by 2050.
Heart Valves 52
52 Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in patients with ADvanced heart failure
American College of Cardiology
OCTOBER 28, 2024
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heart failure and moderate aortic stenosis (stage B aortic stenosis).
Aortic valve 50
50 
Management of acute decompensated valvular heart disease
European Journal of Heart Failure
DECEMBER 11, 2024
Abstract Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.
Transcatheter aortic valve replacement in heart failure
European Journal of Heart Failure
JANUARY 31, 2024
TAVR in heart failure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes.
Aortic valve 40
40 
MindMics Demonstrates Its In-ear Infrasonic Earbud Technology Shows Promise in Detection of Aortic Stenosis and Hearing Heart Murmurs
DAIC
DECEMBER 26, 2023
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter Aortic Valve Replacement (TAVR). We propose a new method of assessing aortic stenosis through IH to detect its characteristic systolic ejection murmur."
Stenosis 59
59 
Severe Mitral Regurgitation in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis
Circulation: Cardiovascular Imaging
MARCH 21, 2025
BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Circulation: Cardiovascular Imaging, Ahead of Print. Subgroups were based on MR severity (severe and nonsevere).
Stenosis 40
40 
ID: 4118785 Predicting Aortic Stenosis in the Community using an Artificial Intelligence Model for 12-lead Electrocardiograms
HeartRhythm
AUGUST 31, 2024
Aortic stenosis (AS) is an increasingly common valvular disease and, if left untreated, can lead to heart failure (HF).
Stenosis 40
40 
Does TAVR Benefit Patients with Moderate Aortic Stenosis and Systolic Heart Failure?
NEJM Journal Watch - Cardiology
MARCH 18, 2025
A small randomized study failed to show a benefit of TAVR in this population.
TAVR 40
40 
Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis
Journal of the American Heart Association
MARCH 13, 2025
Journal of the American Heart Association, Ahead of Print. BackgroundLp(a) (lipoprotein(a)) is an independent risk factor for calcific aortic valve stenosis (CAVS). Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events is unknown. The maximal followup time was set to 5 years.
Aortic valve 45
45 
Management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis
Open Heart
MAY 17, 2022
Objectives The management of severe aortic stenosis mandates consideration of aortic valve intervention for symptomatic patients. However, for asymptomatic patients with severe aortic stenosis, recent randomised trials supported earlier intervention. to 0.96; I 2 15%). to 0.56; I 2 77%).
Stenosis 40
40 Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy
Circulation: Heart Failure
JANUARY 28, 2025
Circulation: Heart Failure, Ahead of Print.
Abstract 4134483: How succesfully can we presribe the 'four pillars' of medications for patients with heart failure with reduced LV systolic function?
Circulation
NOVEMBER 11, 2024
Introduction:European, American and UK guidelines all endorse the prescription of the 'four pillars' of treatment (ACE/ARBs, b-blockers, MRAs and SGLT2 inhibitors) for heart failure with reduced LV systolic function (HFrEF). Circulation, Volume 150, Issue Suppl_1 , Page A4134483-A4134483, November 12, 2024.
Too fast, too furious
Heart BMJ
SEPTEMBER 16, 2024
Clinical introduction A woman in her 30s, a case of rheumatic mitral stenosis status post balloon mitral valvuloplasty 15 years prior, presented to urgent care with palpitations and dyspnoea for 1 week. She was noted to be in heart failure, with hypotension and tachycardia.
Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes
DAIC
JANUARY 29, 2024
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates. for SAVR vs. 0.4%
Aortic valve 111
111 
Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes
European Journal of Heart Failure
OCTOBER 30, 2023
Assessment of fluid overload identifies aortic stenosis (AS) patients at high risk and treatment of fluid overload may potentially improve the post-interventional clinical course. Aims Cardiac decompensation in aortic stenosis (AS) involves extra-valvular cardiac damage and progressive fluid overload (FO).
Stenosis 40
40 
Prognostic effect of stress hyperglycemia ratio on patients with severe aortic stenosis receiving transcatheter aortic valve replacement: a prospective cohort study
Cardiovascular Diabetology
FEBRUARY 15, 2024
Stress hyperglycemia ratio (SHR) has recently been recognized as a novel biomarker that accurately reflects acute hyperglycemia status and is associated with poor prognosis of heart failure. We evaluated the r.
Aortic valve 52
52 
FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve
DAIC
FEBRUARY 15, 2024
Advances in Transcatheter Tricuspid Valve Technologies VIDEO: Tricuspid Device Clinical Trial Overview — Interview with Ori Ben-Yehuda, M.D.
Tricuspid 102
102 
Intravascular lithotripsy (IVL) enabled the percutaneous closure of a severely calcified paravalvular leak regurgitation following implantation of a self-expandable transcatheter aortic valve: a case report
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2024
Case summary An 85-year-old woman suffering from long-standing atrial fibrillation and severe symptomatic aortic stenosis underwent SE TAVI (26 mm Evolut™ R®, Medtronic Inc.,
Aortic valve 111
111 
Medtronic Launches the Avalus Ultra Valve Engineered for Ease of Use at Implant and Lifetime Patient Management
DAIC
APRIL 23, 2024
Aortic stenosis is a common heart problem typically caused by a narrowing of the heart’s aortic valve due to excessive calcium deposited on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body.
Aortic valve 111
111 
AISAP’s CARDIO AI-powered Diagnostic Assessment Software Receives FDA Clearance
DAIC
AUGUST 27, 2024
We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Standalone performance for significant major valve disease pathology (aortic stenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.
Ultrasound 98
98 
Medtronic Launches the Avalus Ultra Valve Engineered for Ease of Use at Implant and Lifetime Patient Management
DAIC
JUNE 13, 2024
Aortic stenosis is a common heart problem typically caused by a narrowing of the heart’s aortic valve due to excessive calcium deposited on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body.
Aortic valve 109
109 
CardioSignal Looks to Expand CVD Detection through Patients Phones
CardiacWire
JANUARY 24, 2024
CardioSignal has already developed digital biomarkers for AFib and heart failure, while more solutions could be on the way for aortic stenosis, coronary artery disease, and pulmonary artery hypertension.
AFIB 75
75 
Impact of serum haemoglobin-to-creatinine ratio after transcatheter aortic valve implantation
Open Heart
DECEMBER 2, 2023
The primary clinical outcome measure was all-cause mortality and heart failure hospitalisation 1 year after TAVI. versus 2.0%, respectively (p<0.01), and that of heart failure hospitalisation was 10.7% for heart failure hospitalisation 1 year after TAVI (OR, 5.3; versus 0.7%, respectively (p<0.01).
Aortic valve 52
52 
Case Report: A case report of myocardial fibrosis activation assessment after unstable angina using 68Ga-FAPI-04 PET/CT
Frontiers in Cardiovascular Medicine
JANUARY 22, 2024
Myocardial ischemia may induce myocardial fibrosis, a condition that progressively leads to ventricular remodeling, heightening the risk of heart failure. In this report, we evaluated a 49-year-old male with UA and severe stenosis in multiple coronary arteries using 68 Ga-FAPI-04 PET/CT.
Angina 69
69 
"Non-STEMI" is a worthless term.
Dr. Smith's ECG Blog
OCTOBER 30, 2023
He had no h/o heart failure. The first hs troponin I returned at 1100 ng/L Angiogram Lesion on 1st Obtuse Marginal : Proximal subsection = 90% stenosis Stented. He has "ischemic cardiomyopathy" and "congestive heart failure." From this most recent "NSTEMI" he developed heart failure, in spite of rapid treatment.
STEMI 123
123 Health Care Cost and Resource Utilization After Aortic Valve Replacement According to the Extent of Cardiac Damage
Circulation: Cardiovascular Interventions
APRIL 7, 2025
However, the association between the extent of cardiac damage at the time of AVR and health care costs and resource utilization has never been described.METHODS:The Optum de-identified Market Clarity database was used to identify patients with aortic stenosis treated with AVR between 2016 and 2022.
Aortic valve 40
40 
Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank
Open Heart
SEPTEMBER 14, 2022
VHD incidence was determined using International Classification of Disease-10 codes for aortic stenosis (AS), aortic regurgitation (AR), mitral stenosis, mitral regurgitation (MR) and mitral valve prolapse. Clinical correlates of VHD included demographics, coronary artery disease, heart failure and atrial fibrillation.
Myocardial sodium–glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO?AS study
European Journal of Heart Failure
JANUARY 21, 2024
Bar plots: in red, patients with low flow-low gradient (LF-LG) aortic stenosis; in blue, patients with normal flow-high gradient (HG) aortic stenosis; in black: controls. Aim Cardiac remodelling plays a major role in the prognosis of patients with aortic stenosis (AS) and could impact the benefits of aortic valve replacement.
Stenosis 40
40 
Cardioprotective effects of semaglutide on isolated human ventricular myocardium
European Journal of Heart Failure
MARCH 19, 2025
Semaglutide reduces late sodium current (I Na ) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end-stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. However, the exact mechanisms underlying its cardioprotective actions remain unclear.
New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance
DAIC
JUNE 7, 2024
Two analyses were presented as late-breaking data at the New York Valves Structural Heart Summit, including a secondary analysis of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial and an expanded analysis of bioprosthetic valve dysfunction (BVD) outcomes from a CoreValve-Evolut pooled analysis. iii Am Heart Assoc.
TAVR 111
111 
Recovery rate from conduction disorders in patients with permanent pacemaker implantation after transcatheter aortic valve implantation
Open Heart
SEPTEMBER 18, 2024
Methods We retrospectively analysed data from 745 consecutive patients who underwent TAVI for severe aortic stenosis from November 2013 to July 2022. Freedom from rehospitalisation due to heart failure rate was significantly higher in the PPMI (–) group (p=0.032). vs 9.1%±9.7%; p=0.035).
Aortic valve 52
52 
See how bad the outcome can be if you don't know OMI findings on the ECG, and don't use the Queen of Hearts
Dr. Smith's ECG Blog
JULY 11, 2024
The red arrow shows a roughly 80% stenosis of the proximal LAD. The blue arrow shows another stenosis of the LAD distal to the first diagonal branch of about 99%. The green arrow shows a 95% stenosis of the ostium of the first diagonal branch. He now has regular appointments with the heart failure team.
Outcomes 113
113 
Let's personalize your content